{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:03:10Z","timestamp":1789437790182,"version":"build-2803163510"},"reference-count":81,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Chemistry &amp;amp; Biodiversity"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Steroidal scaffolds, owing to their inherent structural rigidity, membrane permeability, and receptor affinity, have emerged as a critical class of molecules in anticancer drug development. This manuscript comprehensively explores the development, FDA\u2010approved drugs such as dexamethasone, prednisone, and abiraterone acetate, synthetic innovations, and clinical potential of steroidal derivatives in anticancer therapy. Glucocorticoids and hormone modulators remain foundational in treating hematologic\u2010 and hormone\u2010dependent cancers. At the same time, recent synthetic hybrids, including triazoles, isatins, pyrimidines, and benzisoselenazolones, have shown enhanced potency and selectivity across solid tumor models. The paper underscores the integration of steroids with potential anticancer activity, kinase inhibitors, and bioactive heterocycles to overcome pharmacokinetic limitations and hormone resistance. Several novel steroidal derivatives have demonstrated potent anticancer activity, as evidenced by low IC\n                    <jats:sub>50<\/jats:sub>\n                    values: compound\n                    <jats:bold>29<\/jats:bold>\n                    (0.34\u00a0\u00b5M),\n                    <jats:bold>30<\/jats:bold>\n                    (0.25\u00a0\u00b5M and 0.28\u00a0\u00b5M),\n                    <jats:bold>32<\/jats:bold>\n                    (0.00083, 0.029, and 0.056\u00a0\u00b5M), and\n                    <jats:bold>36<\/jats:bold>\n                    (0.34\u00a0\u00b5M). These findings underscore their strong cytotoxic potential against cancer cell lines. The central perspective emphasizes the resurgence of steroid\u2010based drug design in the precision medicine era, especially in the context of emerging synthetic strategies and their translational viability in resistant and metastatic cancer phenotypes. Furthermore, several investigational steroid\u2010drug combinations are currently being evaluated in clinical trials for advanced\u2010stage cancers, including prostate, breast, and head and neck malignancies, underscoring their translational potential. This review highlights both the therapeutic promise and future directions of steroidal anticancer agent, reinforcing their value as a cornerstone in the development of targeted and supportive cancer therapy.\n                  <\/jats:p>","DOI":"10.1002\/cbdv.202502639","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T20:21:13Z","timestamp":1764793273000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Steroidal Scaffolds as Anticancer Agents: Evolution, FDA Approvals, Synthetic Derivatives, SAR Profiles, and Translational Perspectives"],"prefix":"10.1002","volume":"23","author":[{"given":"Prabhugouda","family":"Gugal","sequence":"first","affiliation":[{"name":"Integrated Drug Discovery Center Acharya &amp; B M Reddy College of Pharmacy  Bengaluru Karnataka India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1206-6712","authenticated-orcid":false,"given":"Hemalatha","family":"Kamurthy","sequence":"additional","affiliation":[{"name":"Integrated Drug Discovery Center Acharya &amp; B M Reddy College of Pharmacy  Bengaluru Karnataka India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2763-5757","authenticated-orcid":false,"given":"Rohit","family":"Pal","sequence":"additional","affiliation":[{"name":"Integrated Drug Discovery Center Acharya &amp; B M Reddy College of Pharmacy  Bengaluru Karnataka India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1978-6029","authenticated-orcid":false,"given":"Gurubasavaraja Swamy","family":"P. M.","sequence":"additional","affiliation":[{"name":"Integrated Drug Discovery Center Acharya &amp; B M Reddy College of Pharmacy  Bengaluru Karnataka India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"M.","sequence":"additional","affiliation":[{"name":"Integrated Drug Discovery Center Acharya &amp; B M Reddy College of Pharmacy  Bengaluru Karnataka India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"C. M","sequence":"additional","affiliation":[{"name":"Integrated Drug Discovery Center Acharya &amp; B M Reddy College of Pharmacy  Bengaluru Karnataka India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koushik","family":"P. M.","sequence":"additional","affiliation":[{"name":"Integrated Drug Discovery Center Acharya &amp; B M Reddy College of Pharmacy  Bengaluru Karnataka India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd18.210006"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2023.2252082"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33232"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.141227"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2196\/43651"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.43198"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16427"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202301200"},{"issue":"3","key":"e_1_2_9_10_1","first-page":"327","article-title":"Progress in Chemotherapy of Cancer","volume":"30","author":"Davis W.","year":"1964","journal-title":"Bulletin of the World Health Organization"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000615)88:12 <3073::AID-CNCR26>3.0.CO;2-R"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1515\/psr\u20102020\u20100206"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2022.02.007"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201007\u20106611"},{"key":"e_1_2_9_15_1","volume-title":"Cancer Chemotherapy and Biotherapy: Principles and Practice","author":"Chabner B. A.","year":"2011"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.297"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2015.03.018"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.09.006"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.936141"},{"key":"e_1_2_9_20_1","volume-title":"Cancer Chemotherapy, Immunotherapy, and Biotherapy","author":"Chabner B. A.","year":"2024"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2025.101102"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqac218"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014\u20100167"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr4002935"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022\u20105347(05)00034\u20100"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.12.013"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102827"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.03.028"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecam\/neh066"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030546"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1515\/jtim\u20102016\u20100011"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1661581"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.11.1"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000069"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncoscience.315"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.883229"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0967199417000545"},{"key":"e_1_2_9_38_1","volume-title":"Antitumor Steroids","author":"Blickenstaff R. T.","year":"2012"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1580"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116266"},{"key":"e_1_2_9_41_1","unstructured":"ClinicalTrails.gov.Abiraterone Acetate in Castration\u2010Resistant Prostate Cancer Previously Treated With Docetaxel\u2010Based Chemotherapy National Library of Medicine; [updated 2014\u201004\u201030; cited 2025 2o June] https:\/\/clinicaltrials.gov\/study\/NCT00638690?intr=NCT00638690&rank=1."},{"key":"e_1_2_9_42_1","unstructured":"ClinicalTrails.gov.A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer` National Library of Medicine; [updated 2025\u201004\u201009; cited 2025 20 June] https:\/\/clinicaltrials.gov\/study\/NCT01602380?intr=NCT01602380&rank=1."},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/14786419.2020.1765347"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.13171"},{"key":"e_1_2_9_45_1","unstructured":"ClinicalTrails.gov Pembrolizumab in Combination With Flutamide Treatment for Recurrence\/Metastasis HNSCC: National Library of Medicine; [updated 2024\u201011\u201019 cited 2025 22 June] https:\/\/clinicaltrials.gov\/study\/NCT06694350?cond=Head%20and%20Neck%20Squamous%20Cell%20Carcinoma&term=PHASE%202&intr=Pembrolizumab%20%2B%20Flutamide&rank=1."},{"key":"e_1_2_9_46_1","unstructured":"ClinicalTrials.gov Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer: National Library of Medicine; [updated 2013\u201012\u201019; cited 2025 22 June] https:\/\/clinicaltrials.gov\/study\/NCT00003717?lat=40.76355319999999&lng=\u201074.30390299999999&locStr=St%20Barnabas%20Medical%20Center%20Emergency%20Room %20Old%20Short%20Hills%20Road %20Livingston %20NJ&distance=50&cond=Prostate%20cancer%09&term=%20Phase\u20102&intr=Estramustine%20%2B%20paclitaxel%09%09%20&rank=1."},{"key":"e_1_2_9_47_1","unstructured":"ClinicalTrials.gov A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer: National Library of Medicine; [updated 2005\u201009\u201022; cited 2025 22 June] https:\/\/clinicaltrials.gov\/study\/NCT00218205?cond=Prostate%20cancer%09&term=%20Phase\u20102&intr=Epirubicin%20%2B%20Estramustine%20Phosphate%20%2B%20Celecoxib%20%09%20%09%20%20&rank=1."},{"key":"e_1_2_9_48_1","unstructured":"ClinicalTrials.gov Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer: National Library of Medicine; [updated 2014\u201001\u201006; cited 2025 22 June] https:\/\/clinicaltrials.gov\/study\/NCT00003066?cond=Metastatic%20Breast%20Cancer%20&term=%20Phase\u20102&intr=Docetaxel%20%2B%20Estramustine%20phosphate%20sodium%20%09%09%09&rank=1."},{"key":"e_1_2_9_49_1","unstructured":"ClinicalTrails.gov Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer: National Library of Medicine; [updated 2014\u201001\u201006; cited 2025 22 June] https:\/\/clinicaltrials.gov\/study\/NCT00002775?cond=metastatic%20prostate%20cancer&term=%20Phase\u20102&intr=Docetaxel%20%2B%20Estramustine%20phosphate%20sodium%20%09%09%09&rank=1."},{"key":"e_1_2_9_50_1","unstructured":"ClinicalTrails.gov Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer: National Library of Medicine; [updated 2013\u201012\u201019; cited 2025 22 June] https:\/\/clinicaltrials.gov\/study\/NCT00003633?cond=%20Prostate%20Cancer%09&term=%20Phase\u20101&intr=Docetaxel%20%2B%20Estramustine%20phosphate%20sodium%20%2B%20mitoxantrone%20hydrochloride%20%2B%20prednisone%20%09%20%09%20&rank=1."},{"issue":"6","key":"e_1_2_9_51_1","first-page":"1185","article-title":"Inhibition of Human Small Cell Lung Cancer Cell Growth by Methylprednisolone","volume":"15","author":"Yamaguchi S.","year":"1999","journal-title":"International Journal of Oncology"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2016.39"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1161768"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28020789"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573406411666150212120628"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549\u2010019\u201005454\u2010y"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(12)70379\u20100"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202100158"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2019.108431"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2023.106386"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568009023334060"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00706\u2010020\u201002716\u20100"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.2174\/97816080549611130201"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201900367"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871520610909040397"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2019.108471"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-814427-5.00008-1"},{"issue":"03","key":"e_1_2_9_68_1","first-page":"10","article-title":"Pyrimidine as Anticancer Agent: A Review","volume":"2","author":"Dudhe R.","year":"2011","journal-title":"Journal of Advanced Scientific Research"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep44439"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28062691"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871520620999201124213655"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.05.006"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1039\/D0OB01241F"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27217456"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/open.201900228"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2019.108502"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.10.063"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2021.106000"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2024.106597"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28020632"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2017.05.013"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2016.11.005"}],"container-title":["Chemistry &amp; Biodiversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cbdv.202502639","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cbdv.202502639","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cbdv.202502639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:30:52Z","timestamp":1775889052000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cbdv.202502639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/cbdv.202502639"],"URL":"https:\/\/doi.org\/10.1002\/cbdv.202502639","archive":["Portico"],"relation":{},"ISSN":["1612-1872","1612-1880"],"issn-type":[{"value":"1612-1872","type":"print"},{"value":"1612-1880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"2025-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02639"}}